Epidermodysplasia verruciformis (EV) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2021 To 2032

Epidermodysplasia verruciformis (EV) is a rare, lifelong, cutaneous, autosomal recessive immune system disorder characterized by increased susceptibility to cutaneous human papillomavirus (HPV) infection beginning in childhood. The disease usually manifests during infancy (7.5% of cases), youth (61.5% of cases), or puberty (22% of cases) with the progressive development of hyperpigmented or hypopigmented flat wart-like papules, irregular reddish-brown plaques, seborrheic keratosis-like lesions and pityriasis Versicolor-like macules on the trunk, neck, face, dorsal hands, and feet. Loss-of-function mutations can cause EV in either of two adjacent genes, EVER1/TMC6 or EVER2/TMC8 (17q25.3), which code for membrane proteins that form a complex with the zinc transporter protein ZnT-1 in the ER membrane of keratinocytes. In epidermodysplasia verruciformis, two clinical presentations have been described. Flat-topped papules and plaques with a scaly surface and irregular borders that are white, pink, reddish-brown, dark brown, or violet. Verrucous or seborrhoeic keratoses-like lesions. These are raised brown warty lesions.

The prevalence of Epidermodysplasia verruciformis (EV) ranges from 0.5 to 0.75 cases per million population in the USA.

 

The competitive landscape of Epidermodysplasia verruciformis (EV) includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Epidermodysplasia verruciformis (EV) across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Epidermodysplasia verruciformis (EV) Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Epidermodysplasia verruciformis (EV) – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2021 To 2032

 

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Metabolic Syndrome – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Type 1 Diabetes Mellitus (T1D) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033